Italian guidelines for the management of irritable bowel syndrome

[1]  P. Iovino,et al.  Pelvic floor biofeedback is an effective treatment for severe bloating in disorders of gut‐brain interaction with outlet dysfunction , 2021, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[2]  A. Greyling,et al.  Correction to: Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis , 2021, European Journal of Nutrition.

[3]  W. Chey,et al.  The low FODMAP diet for IBS; A multicentre UK study assessing long term follow up. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[4]  I. Sporea,et al.  Romanian Guidelines for Nonpharmacological Therapy of IBS. , 2021, Journal of gastrointestinal and liver diseases : JGLD.

[5]  V. Casolaro,et al.  Food Allergy and Intolerance: A Narrative Review on Nutritional Concerns , 2021, Nutrients.

[6]  A. Ford,et al.  British Society of Gastroenterology guidelines on the management of irritable bowel syndrome , 2021, Gut.

[7]  M. Fox,et al.  Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet compared with traditional dietary advice for diarrhea-predominant irritable bowel syndrome: a parallel-group, randomized controlled trial with analysis of clinical and microbiological factors associated with patient o , 2021, The American journal of clinical nutrition.

[8]  Joseph W. Newman,et al.  Loperamide: an emerging drug of abuse and cause of prolonged QTc. , 2021, Clinical medicine.

[9]  B. Cukrowska,et al.  The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study , 2021, Nutrients.

[10]  R. Witkamp,et al.  Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing. , 2021, Cannabis and cannabinoid research.

[11]  S. Taylor-Phillips,et al.  Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the THIN data , 2021, BMJ Open.

[12]  R. Spiller.  Impact of Diet on Symptoms of the Irritable Bowel Syndrome , 2021, Nutrients.

[13]  D. Drossman,et al.  Deconstructing stigma as a barrier to treating DGBI: Lessons for clinicians , 2021, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[14]  A. Gupta,et al.  Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome , 2021, Medicine.

[15]  J. Raes,et al.  Local immune response to food antigens drives meal-induced abdominal pain , 2021, Nature.

[16]  W. Chey,et al.  ACG Clinical Guideline: Management of Irritable Bowel Syndrome. , 2020, The American journal of gastroenterology.

[17]  W. Chey,et al.  Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2) , 2020, The American journal of gastroenterology.

[18]  Heping Zhang,et al.  Adjunctive treatment with probiotics partially alleviates symptoms and reduces inflammation in patients with irritable bowel syndrome , 2020, European Journal of Nutrition.

[19]  M. Bellini,et al.  Low Fermentable Oligo- Di- and Mono-Saccharides and Polyols (FODMAPs) or Gluten Free Diet: What Is Best for Irritable Bowel Syndrome? , 2020, Nutrients.

[20]  O. B. Schaffalitzky de Muckadell,et al.  A positive diagnostic strategy is safe and saves endoscopies in patients with irritable bowel syndrome: A five‐year follow‐up of a randomized controlled trial , 2020, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[21]  M. Weickert,et al.  The Health Benefits of Dietary Fibre , 2020, Nutrients.

[22]  Hannah J. Craven,et al.  Potential Benefit with Complementary and Alternative Medicine in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[23]  M. Kurien,et al.  Diagnostic Yield of Colonoscopy in Patients with Symptoms Compatible with Rome IV Functional Bowel Disorders. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  M. Bellini,et al.  A Low-FODMAP Diet for Irritable Bowel Syndrome: Some Answers to the Doubts from a Long-Term Follow-Up , 2020, Nutrients.

[25]  B. Lacy,et al.  Diagnosing Small Intestinal Bacterial Overgrowth: A Comparison of Lactulose Breath Tests to Small Bowel Aspirates , 2020, Digestive Diseases and Sciences.

[26]  J. Murray,et al.  AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. , 2020, Gastroenterology.

[27]  S. Lapin,et al.  Automated Fecal Biomarker Profiling - a Convenient Procedure to Support Diagnosis for Patients with Inflammatory Bowel Diseases. , 2020, Clinical Laboratory.

[28]  J. Jansen,et al.  Analytical and clinical performance of the fully-automated LIAISONXL calprotectin immunoassay from DiaSorin in IBD patients , 2020, Practical laboratory medicine.

[29]  R. Fathi,et al.  Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial. , 2020, The American journal of gastroenterology.

[30]  A. Abdelnour,et al.  Prevalence of IgE‐mediated sensitization in patients with suspected food allergic reactions in Jordan , 2020, Immunity, inflammation and disease.

[31]  M. Camilleri,et al.  The Role of Bile Acids in Chronic Diarrhea. , 2020, The American journal of gastroenterology.

[32]  A. Ford,et al.  Best management of irritable bowel syndrome , 2020, Frontline Gastroenterology.

[33]  K. Whelan,et al.  β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria. , 2020, The American journal of gastroenterology.

[34]  V. Anttila,et al.  Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome , 2020, Alimentary pharmacology & therapeutics.

[35]  P. Whorwell,et al.  Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. , 2020, Gastroenterology.

[36]  P. Moayyedi,et al.  Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis , 2020, Gut.

[37]  P. Layer,et al.  Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. , 2020, The lancet. Gastroenterology & hepatology.

[38]  T. Tompkins,et al.  Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study , 2020, Nutrients.

[39]  P. Moayyedi,et al.  Evidence-based and mechanistic insights into exclusion diets for IBS , 2020, Nature Reviews Gastroenterology & Hepatology.

[40]  A. Lembo,et al.  Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea , 2020, Clinical and translational gastroenterology.

[41]  Maryanne Martin,et al.  A randomized clinical trial of mindfulness-based cognitive therapy for women with irritable bowel syndrome-Effects and mechanisms. , 2020, Journal of consulting and clinical psychology.

[42]  S. Sennoune,et al.  A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. , 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[43]  W. Chey,et al.  Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1) , 2020, The American journal of gastroenterology.

[44]  N. Talley,et al.  Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. , 2020, The American journal of gastroenterology.

[45]  J. Harnett,et al.  Western herbal medicines in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. , 2020, Complementary therapies in medicine.

[46]  M. Bellini,et al.  Low FODMAP Diet: Evidence, Doubts, and Hopes , 2020, Nutrients.

[47]  O. Gilja,et al.  Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study , 2019, Gut.

[48]  U. Ghoshal,et al.  A meta‐analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome , 2019, Journal of gastroenterology and hepatology.

[49]  Tanisa Patcharatrakul,et al.  Effect of Structural Individual Low-FODMAP Dietary Advice vs. Brief Advice on a Commonly Recommended Diet on IBS Symptoms and Intestinal Gas Production , 2019, Nutrients.

[50]  M. Pimentel,et al.  Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea , 2019, The American journal of gastroenterology.

[51]  M. Heitkemper,et al.  Effects of a comprehensive self-management intervention on extraintestinal symptoms among patients with IBS. , 2019, Journal of psychosomatic research.

[52]  M. Camilleri,et al.  Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. , 2019, The lancet. Gastroenterology & hepatology.

[53]  R. Di Santo,et al.  Tegaserod for the Treatment of Irritable Bowel Syndrome , 2019, Anti-inflammatory & anti-allergy agents in medicinal chemistry.

[54]  S. Landau,et al.  Cognitive behavioural therapy for irritable bowel syndrome: 24-month follow-up of participants in the ACTIB randomised trial , 2019, The lancet. Gastroenterology & hepatology.

[55]  M. Simrén,et al.  The Dietary Management of Patients with Irritable Bowel Syndrome: A Narrative Review of the Existing and Emerging Evidence , 2019, Nutrients.

[56]  W. Chey,et al.  AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults. , 2019, Gastroenterology.

[57]  F. Ghazanfari,et al.  Comparison of the Effect of Dialectical Behavior Therapy, Mindfulness Based Cognitive Therapy and Positive Psychotherapy on Perceived Stress and Quality of Life in Patients with Irritable Bowel Syndrome: a Pilot Randomized Controlled Trial , 2019, Psychiatric Quarterly.

[58]  H. Frijlink,et al.  Efficacy and Safety of Peppermint Oil in a Randomized Double-blind Trial of Patients With Irritable Bowel Syndrome. , 2019, Gastroenterology.

[59]  A. Gasbarrini,et al.  Systematic review with meta‐analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome , 2019, Alimentary pharmacology & therapeutics.

[60]  M. Schmulson,et al.  Fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta-analysis , 2019, United European gastroenterology journal.

[61]  I. Hall,et al.  Abnormalities of mucosal serotonin metabolism and 5‐HT3 receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron , 2019, Alimentary pharmacology & therapeutics.

[62]  J. Jaccard,et al.  Factors Associated With Efficacy of Cognitive Behavior Therapy vs Education for Patients With Irritable Bowel Syndrome. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[63]  M. Zamani,et al.  Systematic review with meta‐analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome , 2019, Alimentary pharmacology & therapeutics.

[64]  P. Gasparini,et al.  IBS clinical management in Italy: The AIGO survey. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[65]  S. Landau,et al.  Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT. , 2019, Health technology assessment.

[66]  P. Moayyedi,et al.  Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis , 2019, Gut.

[67]  S. Landau,et al.  Assessing telephone-delivered cognitive–behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial , 2019, Gut.

[68]  A. Gasbarrini,et al.  Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. , 2019, European review for medical and pharmacological sciences.

[69]  L. T. Te Morenga,et al.  Carbohydrate quality and human health: a series of systematic reviews and meta-analyses , 2019, The Lancet.

[70]  A. Zinsmeister,et al.  Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome , 2019, Alimentary pharmacology & therapeutics.

[71]  P. Moayyedi,et al.  Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS) , 2019, Journal of the Canadian Association of Gastroenterology.

[72]  G. Mullin,et al.  The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data , 2019, BMC Complementary and Alternative Medicine.

[73]  G. Zuccotti,et al.  Efficacy of the gluten free diet in the management of functional gastrointestinal disorders: a systematic review on behalf of the Italian Society of Paediatrics , 2019, Italian Journal of Pediatrics.

[74]  M. Bellini,et al.  Pelvic floor rehabilitation for defecation disorders , 2019, Techniques in Coloproctology.

[75]  U. Ghoshal,et al.  Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. , 2019, Gastroenterology.

[76]  M. Ventura,et al.  Pre‐ and probiotic overview , 2018, Current opinion in pharmacology.

[77]  P. Moayyedi,et al.  Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. , 2018, Gastroenterology.

[78]  P. Moayyedi,et al.  Systematic review with meta‐analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome , 2018, Alimentary pharmacology & therapeutics.

[79]  A. Arj,et al.  A randomized clinical trial of the Unified Protocol for Transdiagnostic treatment of emotional and gastrointestinal symptoms in patients with irritable bowel syndrome: evaluating efficacy and mechanism of change. , 2018, Journal of psychosomatic research.

[80]  M. Thapa,et al.  Clinical Features and Visual outcome in Acute and Recurrent Case of Optic Neuritis. , 2018, Nepal medical journal .

[81]  P. Moayyedi,et al.  A Systematic Review and Meta‐Analysis Evaluating the Efficacy of a Gluten‐Free Diet and a Low FODMAPS Diet in Treating Symptoms of Irritable Bowel Syndrome , 2018, The American Journal of Gastroenterology.

[82]  Wei Wei,et al.  Therapeutic Effect of Chang’an I Recipe (肠安 I 号方) on Irritable Bowel Syndrome with Diarrhea: A Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial , 2018, Chinese Journal of Integrative Medicine.

[83]  S. Abdi,et al.  Comparing the Efficacy of Mindfulness-Based Stress Reduction Therapy with Emotion Regulation Treatment on Quality of Life and Symptoms of Irritable Bowel Syndrome , 2018, Iranian journal of psychiatry.

[84]  P. H. Green,et al.  Global Prevalence of Celiac Disease: Systematic Review and Meta‐analysis , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[85]  J. Larson,et al.  Celiac disease is uncommon in irritable bowel syndrome in the USA , 2018, European journal of gastroenterology & hepatology.

[86]  P. Schoenfeld,et al.  Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis , 2018, The American Journal of Gastroenterology.

[87]  D. Sanders,et al.  Coeliac disease , 2018, The Lancet.

[88]  Xiuli Zuo,et al.  Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials , 2018, BMC Gastroenterology.

[89]  K. Whelan,et al.  Long‐term impact of the low‐FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome , 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[90]  D. Drossman,et al.  Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. , 2017, Gastroenterology.

[91]  T. Chalder,et al.  The journey between brain and gut: A systematic review of psychological mechanisms of treatment effect in irritable bowel syndrome. , 2017, British journal of health psychology.

[92]  M. Camilleri,et al.  Pharmacotherapy for Irritable Bowel Syndrome , 2017, Journal of clinical medicine.

[93]  K. Whelan,et al.  A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial. , 2017, Gastroenterology.

[94]  Ather Ali,et al.  Efficacy of individualised diets in patients with irritable bowel syndrome: a randomised controlled trial , 2017, BMJ open gastroenterology.

[95]  M. Schultz,et al.  Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs , 2017, World journal of gastroenterology.

[96]  P. Schoenfeld,et al.  Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity , 2017, Digestive Diseases and Sciences.

[97]  F. Azpiroz,et al.  Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome , 2017, Alimentary pharmacology & therapeutics.

[98]  M. Camilleri,et al.  Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. , 2017, Gastroenterology.

[99]  T. Hausken,et al.  Effects of varying dietary content of fermentable short‐chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome , 2017, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[100]  J. Tack,et al.  Therapeutic Advances in Gastroenterology , 2022 .

[101]  S. Passaretti,et al.  Chronic constipation diagnosis and treatment evaluation: the “CHRO.CO.DI.T.E.” study , 2017, BMC Gastroenterology.

[102]  P. Schoenfeld,et al.  Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea , 2016, The American Journal of Gastroenterology.

[103]  P. Schoenfeld,et al.  Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. , 2016, Gastroenterology.

[104]  W. Chey,et al.  A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D , 2016, The American Journal of Gastroenterology.

[105]  M. Lomer,et al.  British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). , 2016, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

[106]  W. Chey,et al.  Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation , 2016, Alimentary pharmacology & therapeutics.

[107]  M. Camilleri,et al.  Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation , 2016, The American Journal of Gastroenterology.

[108]  D. Drossman,et al.  Biopsychosocial Aspects of Functional Gastrointestinal Disorders. , 2016, Gastroenterology.

[109]  V. Naganathan,et al.  Comparison of the effectiveness of polyethylene glycol with and without electrolytes in constipation: a systematic review and network meta-analysis , 2016, BMC Gastroenterology.

[110]  A. Keshteli,et al.  FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial , 2016, Gut.

[111]  L. Turner,et al.  Eluxadoline for Irritable Bowel Syndrome with Diarrhea. , 2016, The New England journal of medicine.

[112]  W. Laan,et al.  Comparison of medical costs generated by IBS patients in primary and secondary care in the Netherlands , 2015, BMC Gastroenterology.

[113]  L. Böhn,et al.  Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. , 2015, Gastroenterology.

[114]  Jin-Ho Kim,et al.  The Diagnostic Value of a Digital Rectal Examination Compared With High-Resolution Anorectal Manometry in Patients With Chronic Constipation and Fecal Incontinence , 2015, The American Journal of Gastroenterology.

[115]  R. Malekzadeh,et al.  Non-Celiac Gluten Sensitivity Has Narrowed the Spectrum of Irritable Bowel Syndrome: A Double-Blind Randomized Placebo-Controlled Trial , 2015, Nutrients.

[116]  S. Rao,et al.  Systematic review: dietary fibre and FODMAP‐restricted diet in the management of constipation and irritable bowel syndrome , 2015, Alimentary pharmacology & therapeutics.

[117]  P. Moayyedi,et al.  Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey , 2015, Scandinavian journal of gastroenterology.

[118]  Jacob E. Kurlander,et al.  A Meta-Analysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin, and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults With IBS , 2015, The American Journal of Gastroenterology.

[119]  A. Zinsmeister,et al.  Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea‐predominant irritable bowel syndrome , 2015, Alimentary pharmacology & therapeutics.

[120]  D. Gorard,et al.  Review article: the diagnosis and management of food allergy and food intolerances , 2015, Alimentary pharmacology & therapeutics.

[121]  W. Whitehead,et al.  Conducting multinational, cross‐cultural research in the functional gastrointestinal disorders: issues and recommendations. A Rome Foundation working team report , 2014, Alimentary pharmacology & therapeutics.

[122]  A. Lembo,et al.  American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. , 2014, Gastroenterology.

[123]  J. West,et al.  The Incidence of Other Gastroenterological Disease following Diagnosis of Irritable Bowel Syndrome in the UK: A Cohort Study , 2014, PloS one.

[124]  P. Moayyedi,et al.  American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation , 2014, The American Journal of Gastroenterology.

[125]  Glenn R. Gibson,et al.  The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic , 2014 .

[126]  R. Cuomo,et al.  Irritable bowel syndrome and food interaction. , 2014, World journal of gastroenterology.

[127]  U. Ghoshal,et al.  Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture , 2014, European journal of gastroenterology & hepatology.

[128]  C. Scarpignato,et al.  Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers. , 2014, Pharmacological research.

[129]  L. Saha.  Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. , 2014, World journal of gastroenterology.

[130]  T. Wittmann,et al.  Role of antispasmodics in the treatment of irritable bowel syndrome. , 2014, World journal of gastroenterology.

[131]  M. Pimentel,et al.  Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome , 2014, Digestive Diseases and Sciences.

[132]  M. Rudling,et al.  Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS , 2014, Gut.

[133]  M. Leboyer,et al.  Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis , 2014, European Archives of Psychiatry and Clinical Neuroscience.

[134]  W. Chey,et al.  Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials , 2014, Alimentary pharmacology & therapeutics.

[135]  K. Whelan,et al.  Mechanisms and efficacy of dietary FODMAP restriction in IBS , 2014, Nature Reviews Gastroenterology &Hepatology.

[136]  I. Hall,et al.  A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea , 2013, Gut.

[137]  K. Garsed,et al.  Faecal microbiota composition and host–microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome , 2013, Gut.

[138]  R. Humphries,et al.  Detection of Intestinal Protozoa in the Clinical Laboratory , 2013, Journal of Clinical Microbiology.

[139]  B. Naliboff,et al.  Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[140]  M. Cicala,et al.  A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders , 2013, United European gastroenterology journal.

[141]  P. Larsen,et al.  A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[142]  T. Ålander,et al.  An international Delphi study to assess the need for multiaxial criteria in diagnosis and management of functional gastrointestinal disorders. , 2013, Journal of psychosomatic research.

[143]  W. Whitehead,et al.  Which psychological factors exacerbate irritable bowel syndrome? Development of a comprehensive model. , 2013, Journal of psychosomatic research.

[144]  L. Böhn,et al.  Self-Reported Food-Related Gastrointestinal Symptoms in IBS Are Common and Associated With More Severe Symptoms and Reduced Quality of Life , 2013, The American Journal of Gastroenterology.

[145]  A. Ford,et al.  Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[146]  W. Chey,et al.  Randomised clinical trials: linaclotide phase 3 studies in IBS‐C – a prespecified further analysis based on European Medicines Agency‐specified endpoints , 2013, Alimentary pharmacology & therapeutics.

[147]  W. Chey,et al.  Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety , 2012, The American Journal of Gastroenterology.

[148]  J. Tack,et al.  Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation , 2012, Expert opinion on drug metabolism & toxicology.

[149]  M. Currie,et al.  A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation , 2012, The American Journal of Gastroenterology.

[150]  A. Zinsmeister,et al.  Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome‐diarrhea , 2012, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[151]  A. Lembo,et al.  Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. , 2012, The American journal of medicine.

[152]  A. Zinsmeister,et al.  Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. , 2011, Gastroenterology.

[153]  K. Whelan,et al.  Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. , 2011, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

[154]  N. D. de Wit,et al.  Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. , 2011, The Cochrane database of systematic reviews.

[155]  S. Gonlachanvit,et al.  Outcome of Biofeedback Therapy in Dyssynergic Defecation Patients With and Without Irritable Bowel Syndrome , 2011, Journal of clinical gastroenterology.

[156]  G. Barlow,et al.  Effects of Rifaximin Treatment and Retreatment in Nonconstipated IBS Subjects , 2011, Digestive Diseases and Sciences.

[157]  W. Chey,et al.  Rifaximin therapy for patients with irritable bowel syndrome without constipation. , 2011, The New England journal of medicine.

[158]  A. Ford,et al.  Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis , 2011, Gut.

[159]  M. Currie,et al.  Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. , 2010, Gastroenterology.

[160]  S. Vanner,et al.  Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS , 2010, Gut.

[161]  K. Tantiphlachiva,et al.  Digital rectal examination is a useful tool for identifying patients with dyssynergia. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[162]  Justin C. Y. Wu.  Complementary and alternative medicine modalities for the treatment of irritable bowel syndrome: facts or myths? , 2010, Gastroenterology & hepatology.

[163]  D. Zeldin,et al.  National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005-2006. , 2010, The Journal of allergy and clinical immunology.

[164]  P. V. van Rheenen,et al.  Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis , 2010, BMJ : British Medical Journal.

[165]  B. Spiegel,et al.  Is Irritable Bowel Syndrome a Diagnosis of Exclusion?: A Survey of Primary Care Providers, Gastroenterologists, and IBS Experts , 2010, The American Journal of Gastroenterology.

[166]  A. Zinsmeister,et al.  Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[167]  P. Moayyedi,et al.  Efficacy of 5-HT3 Antagonists and 5-HT4 Agonists in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis , 2009, The American Journal of Gastroenterology.

[168]  W. Chey,et al.  Clinical trial: lubiprostone in patients with constipation‐associated irritable bowel syndrome – results of two randomized, placebo‐controlled studies , 2009, Alimentary pharmacology & therapeutics.

[169]  M. Lyon,et al.  Celiac disease and IgA deficiency: complications of serological testing approaches encountered in the clinic. , 2008, Clinical chemistry.

[170]  M. Camilleri,et al.  Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[171]  S. Nikfar,et al.  Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. , 2008, Clinical therapeutics.

[172]  D. Drossman,et al.  Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation , 2008, Alimentary pharmacology & therapeutics.

[173]  A. Michalsen,et al.  Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices , 2008, The American Journal of Gastroenterology.

[174]  A. Schoepfer,et al.  Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies , 2008, Inflammatory bowel diseases.

[175]  Colin Summers,et al.  The prevalence of food allergy: a meta-analysis. , 2007, The Journal of allergy and clinical immunology.

[176]  M. Crowell,et al.  Irritable bowel syndrome: patients’ attitudes, concerns and level of knowledge , 2007, Alimentary pharmacology & therapeutics.

[177]  J. Mcgowan,et al.  A Randomized, Multicenter, Placebo-Controlled Trial of Polyethylene Glycol Laxative for Chronic Treatment of Chronic Constipation , 2007, The American Journal of Gastroenterology.

[178]  M. Pimentel,et al.  The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome , 2006, Annals of Internal Medicine.

[179]  P. Vandvik,et al.  Perceived food intolerance in subjects with irritable bowel syndrome – etiology, prevalence and consequences , 2006, European Journal of Clinical Nutrition.

[180]  W. Chey,et al.  Incidence of Ischemic Colitis and Serious Complications of Constipation Among Patients Using Alosetron: Systematic Review of Clinical Trials and Post-Marketing Surveillance Data , 2006, The American Journal of Gastroenterology.

[181]  P. Bruzzi,et al.  The general practitioner's approach to irritable bowel syndrome: from intention to practice. , 2005, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[182]  S. H. Arshad,et al.  Prevalence of sensitization to food allergens, reported adverse reaction to foods, food avoidance, and food hypersensitivity among teenagers. , 2005, The Journal of allergy and clinical immunology.

[183]  S. Collins,et al.  Is irritable bowel syndrome a low-grade inflammatory bowel disease? , 2005, Gastroenterology clinics of North America.

[184]  G. Roberts,et al.  Diagnosing peanut allergy with skin prick and specific IgE testing. , 2005, The Journal of allergy and clinical immunology.

[185]  C. Ihlebæk,et al.  Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications , 2004, Alimentary pharmacology & therapeutics.

[186]  T. Sheldon,et al.  Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial , 2004, Gut.

[187]  M. Camilleri,et al.  The Role of Pelvic Floor Dysfunction and Slow Colonic Transit in Adolescents with Refractory Constipation , 2004, American Journal of Gastroenterology.

[188]  B. Spiegel,et al.  Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. , 2004, Gastroenterology.

[189]  B. Sands,et al.  Occurrence of Colon Ischemia in Relation to Irritable Bowel Syndrome , 2004, American Journal of Gastroenterology.

[190]  S. Chaussade,et al.  Comparison of efficacy and safety of two doses of two different polyethylene glycol‐based laxatives in the treatment of constipation , 2003, Alimentary pharmacology & therapeutics.

[191]  W. Chey,et al.  The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review , 2002, American Journal of Gastroenterology.

[192]  I. Forgacs,et al.  Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. , 2002, Gastroenterology.

[193]  M. Camilleri.  Review article: tegaserod. , 2001, Alimentary pharmacology & therapeutics.

[194]  B. Kolts,et al.  A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative , 2000, American Journal of Gastroenterology.

[195]  W. Paterson,et al.  Predictive value of the rome criteria for diagnosing the irritable bowel syndrome , 1999, American Journal of Gastroenterology.

[196]  C. Hunt,et al.  Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria , 1999, American Journal of Gastroenterology.

[197]  P. Whorwell,et al.  Bran and irritable bowel syndrome: time for reappraisal , 1994, The Lancet.

[198]  R. Rona,et al.  A population study of food intolerance , 1994, The Lancet.

[199]  A. Williams,et al.  Idiopathic bile acid malabsorption--a review of clinical presentation, diagnosis, and response to treatment. , 1991, Gut.

[200]  G. Holmes,et al.  Malignancy in coeliac disease--effect of a gluten free diet. , 1989, Gut.

[201]  B. Grigolo,et al.  75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit. , 1987, Gut.

[202]  D. Barends,et al.  Role of loperamide and placebo in management of irritable bowel syndrome (IBS) , 1984, Digestive Diseases and Sciences.

[203]  A. Hofmann.  Bile acid malabsorption caused by ileal resection. , 1972, Archives of internal medicine.

[204]  P. Whorwell,et al.  Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE): a multicentre randomised controlled trial. , 2019, The lancet. Gastroenterology & hepatology.

[205]  K. Kennedy,et al.  The Contributions of Internal Intussusception, Irritable Bowel Syndrome, and Pelvic Floor Dyssynergia to Obstructed Defecation Syndrome , 2019, Diseases of the colon and rectum.

[206]  M. F. Alexander C. Ford MB ChB,et al.  American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome , 2018, The American Journal of Gastroenterology.

[207]  M. F. Brian E. Lacy PhD,et al.  Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis , 2018, The American Journal of Gastroenterology.

[208]  P. F. F. A. Satish S. C. Rao MD.  Rectal Exam: Yes, it can and should be done in a busy practice! , 2018, The American Journal of Gastroenterology.

[209]  Rémi Brazeilles,et al.  Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome. , 2017, Gastroenterology.

[210]  W. Chey,et al.  Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis , 2017, The American Journal of Gastroenterology.

[211]  R. Spiller,et al.  Bowel Disorders. , 2016, Gastroenterology.

[212]  P. Ducrotte,et al.  Tolerance and long-term efficacy of polyethylene glycol 4000 (Forlax®) compared to lactulose in elderly patients with chronic constipation , 2016, The journal of nutrition, health & aging.

[213]  A. Malcolm,et al.  Functional Anorectal Disorders. , 2016, Gastroenterology.

[214]  P. Gibson,et al.  A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. , 2014, Gastroenterology.

[215]  Gurkirpal Singh,et al.  Diagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organization. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[216]  J. Muir,et al.  Gluten Causes Gastrointestinal Symptoms in Subjects Without Celiac Disease: A Double-Blind Randomized Placebo-Controlled Trial , 2011, The American Journal of Gastroenterology.

[217]  N. D. de Wit,et al.  Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome , 2008 .

[218]  M. Pimentel,et al.  Rifaximin versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS , 2007, Digestive Diseases and Sciences.

[219]  J. Fahrenholz,et al.  Food allergy , 2002, Current treatment options in gastroenterology.

[220]  R. Jones,et al.  Irritable bowel syndrome. , 1991, The Practitioner.